Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

A research team has developed a multi-medium approach (MMA) to identify reproducible volatile organic compounds (VOCs) in ...